

## Chemotherapy Treatment Note

**Patient:** Lisa Miller **MRN:** SYN234 **DOB:** 02/15/1973 (50 y/o F)

**Visit Date:** 11/20/2023 **Treatment:** Cycle 2, Day 1 (Carbo/Pem/Pembro)

**Diagnosis:** Metastatic NSCLC (Adenocarcinoma), LUL primary, solitary RUL lung met. Stage IVA (T2aN0M1a). Dx 10/05/23. WT/PD-L1 Negative (0%).

**Treatment Regimen:** Carboplatin (AUC 5) + Pemetrexed (500 mg/m<sup>2</sup>) + Pembrolizumab (200 mg) IV q3 weeks. Cycle 1 initiated 10/27/23.

### Pre-Treatment Assessment (C2D1):

Patient presents for Cycle 2 Day 1. Reports Cycle 1 tolerance as "okay," but with notable side effects.

- **Nausea:** Grade 2, days 2-4, required PRN prochlorperazine. Resolved.
- **Fatigue:** Grade 2-3, worst days 5-14, improved but still present (baseline ECOG 0, now ECOG 1).
- **Hematologic:** Nadir labs day 10 showed G1 neutropenia/anemia/thrombocytopenia. No febrile events.
- **Other:** Mild constipation, no mucositis, no irAE symptoms reported.
- **Anxiety:** Baseline GAD stable on Escitalopram. Patient feels ready for C2.

**Vitals & Exam:** Afebrile, HR 78, BP 116/70. Wt down 2 lbs. Exam unremarkable. ECOG 1.

### Labs Today (Pre-Chemo):

- WBC 4.5, ANC 2.8, Hgb 11.8, Plt 185. (Counts adequate).
- Cr 0.7, LFTs WNL.

**Toxicity Assessment:** Cycle 1 Toxicities: Nausea (G2), Fatigue (G3), Anemia (G1), Neutropenia (G1), Thrombocytopenia (G1).

### Plan for Cycle 2:

1. **Proceed with C2D1:** Carboplatin/Pemetrexed/Pembrolizumab at 100% planned doses.
2. **Premedications:** IV Aprepitant 150mg, Ondansetron 16mg, Dexamethasone 12mg. 1L NS hydration.
3. **Post-Chemo Meds / Instructions:**
  - Aprepitant 80mg PO tomorrow and day after (Days 2 & 3).
  - *Emphasized* taking PRN Prochlorperazine 10mg PO q6h scheduled for first 3 days post-chemo, then PRN, to better manage nausea.
  - Continue Folic Acid daily, Vitamin B12 injection next cycle.

- o Reinforced energy conservation, hydration, nutrition.
- o Strict fever/infection precautions reviewed. Call clinic/on-call for T > 100.4 F, chills, or other concerns. Provided contact numbers.

**4. Follow-up:**

- o Nadir lab check (CBC, CMP) in 7-10 days.
- o Return for Cycle 3 Day 1 in 3 weeks (approx. 12/11/23).
- o First restaging scans planned after Cycle 4.

**Infusion:** Tolerated infusions well without immediate reaction. Patient discharged home in stable condition.

**Electronically Signed By:**

Patricia Chen, MD

Medical Oncology

Date/Time: 11/20/2023 14:00